Log In
BCIQ
Print this Print this
 

JZP-386 (formerly C-10323)

  Manage Alerts
Collapse Summary General Information
Company Concert Pharmaceuticals Inc.
DescriptionDeuterium-modified sodium oxybate compound
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationExcessive sleepiness
Indication DetailsTreat narcolepsy
Regulatory Designation
PartnerJazz Pharmaceuticals plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2013

Undisclosed

Undisclosed

$120.0M

Get a free BioCentury trial today